title: Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers.
abstract: Pregabalin is an anticonvulsant drug indicated for neuropathic disorders and fibromyalgia. Some chronic pain patients suffering from these disorders take both this drug and an opioid for pain relief. Pregabalin is a scheduled drug under the Controlled Substances Act. The subjective effects of this drug have not been well-characterized, and the extent to which it alters the subjective effects of opioids has not been studied to the best of our knowledge. Using a double-blind, randomized, crossover design, 16 healthy volunteers were administered (in separate sessions) capsules containing placebo, 75 mg pregabalin, 150 mg pregabalin, 10 mg oxycodone, and 75 mg pregabalin combined with 10 mg oxycodone. Subjective, psychomotor, and physiological measures were assessed during each of the five sessions. Pregabalin produced dose-related increases in some subjective effects and decreased respiration rate, but did not impact on psychomotor performance. Abuse liability-related subjective effects such as drug liking and desire to take the drug again were not increased by either pregabalin dose. Oxycodone produced increases in several subjective effects, including ratings of drug liking. When 75 mg pregabalin was combined with oxycodone some subjective effects were altered relative to placebo, in contrast to when each drug was tested alone. Liking of oxycodone was not increased by 75 mg pregabalin. However, recent studies have suggested that this drug is abused, and we would recommend that further psychopharmacological studies with pregabalin are warranted, including a study assessing its abuse liability across a range of doses in sedative abusers.
authors.affiliation: Department of Anesthesia & Critical Care, The University of Chicago, Chicago, IL 60637, USA. jzacny@dacc.uchicago.edu
authors.forename: James P
authors.initials: JP
authors.lastname: Zacny
authors.forename: Judith A
authors.initials: JA
authors.lastname: Paice
authors.forename: Dennis W
authors.initials: DW
authors.lastname: Coalson
mesh_terms: D000328:Adult; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects*; D000701:Analgesics, Opioid / Q000009:adverse effects*; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004338:Drug Combinations; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D020258:Neurotoxicity Syndromes / Q000503:physiopathology* / Q000523:psychology; D009293:Opioid-Related Disorders / Q000523:psychology; D010098:Oxycodone / Q000009:adverse effects*; D000069583:Pregabalin; D011597:Psychomotor Performance / Q000187:drug effects; D056152:Respiratory Rate / Q000187:drug effects; D019966:Substance-Related Disorders / Q000523:psychology; D023382:Toxicity Tests, Acute; D055815:Young Adult; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000700:Analgesics; D000701:Analgesics, Opioid; D000927:Anticonvulsants; D004338:Drug Combinations; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D010098:Oxycodone
references.citation: Curr Opin Pharmacol. 2006 Feb;6(1):108-13
references.pmid: 16376147
references.citation: Arch Gen Psychiatry. 1983 Aug;40(8):865-73
references.pmid: 6870483
references.citation: Arch Gen Psychiatry. 2006 Oct;63(10):1149-57
references.pmid: 17015817
references.citation: J Am Osteopath Assoc. 2010 Oct;110(10):605-7
references.pmid: 21068226
references.citation: Clin Pharmacol Ther. 1971 Mar-Apr;12(2):245-58
references.pmid: 5554941
references.citation: Neurology. 2010 Mar 2;74(9):755-61
references.pmid: 20194915
references.citation: Eur Neurol. 2011;65(6):317-22
references.pmid: 21576968
references.citation: Psychother Psychosom. 2011;80(2):118-22
references.pmid: 21212719
references.citation: J Pharmacol Exp Ther. 1995 Feb;272(2):570-80
references.pmid: 7853170
references.citation: Clin Drug Investig. 2009;29(3):203-13
references.pmid: 19243212
references.citation: J Pharmacol Exp Ther. 1961 Sep;133:371-87
references.pmid: 13701509
references.citation: Psychopharmacology (Berl). 2011 Dec;218(3):471-81
references.pmid: 21603891
references.citation: Psychopharmacology (Berl). 2008 Jan;196(1):105-16
references.pmid: 17899018
references.citation: Pain Pract. 2003 Dec;3(4):317-20
references.pmid: 17166127
references.citation: Clin J Pain. 2009 Jul-Aug;25(6):528-36
references.pmid: 19542802
references.citation: Pharmacol Toxicol. 1991 May;68(5):360-5
references.pmid: 1946181
references.citation: Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17537-42
references.pmid: 17088553
references.citation: J Pharmacol Exp Ther. 1984 May;229(2):501-8
references.pmid: 6716272
references.citation: Curr Med Res Opin. 2004 May;20(5):577-80
references.pmid: 15140322
references.citation: Psychopharmacology (Berl). 2005 Dec;183(2):133-43
references.pmid: 16205916
references.citation: Eur J Clin Pharmacol. 2010 Sep;66(9):947-53
references.pmid: 20563568
references.citation: Drug Alcohol Depend. 2010 Mar 1;107(2-3):209-14
references.pmid: 19948383
references.citation: Psychol Rep. 1966 Feb;18(1):163-94
references.pmid: 5908477
references.citation: Anesth Analg. 2007 Dec;105(6):1805-15
references.pmid: 18042886
references.citation: Psychopharmacology (Berl). 2003 Nov;170(3):242-254
references.pmid: 12955305
references.citation: Mayo Clin Proc. 2010 Mar;85(3 Suppl):S3-14
references.pmid: 20194146
references.citation: J Pharmacol Exp Ther. 1989 Jul;250(1):184-96
references.pmid: 2473187
references.citation: Pharmacol Biochem Behav. 2011 Nov;100(1):138-43
references.pmid: 21884720